Abstract Alzheimer's disease (AD) is a genetically complex disorder, and several genes related to cholesterol metabolism have been reported to contribute to AD risk.
Introduction
Cholesterol influences processes that are central to the pathogenesis of Alzheimer's disease (AD) [1] . In support of experimental and epidemiological evidence, population genetics suggest a role of cholesterol in the pathophysiology of AD [2] . The ɛ4 allele of APOE, the gene encoding the major apolipoprotein of the central nervous system is the only well-established genetic risk factor for sporadic AD. However, several other genes related to cholesterol metabolism have been associated with AD risk, albeit with conflicting findings in subsequent replication trials (The AlzGene Database, http://www.alzgene.org). With respect to the complex nature of the genetics of both cholesterol metabolism and AD, we have recently conducted a set association study in which we have shown an additive effect of polymorphisms in cholesterol-related genes for which association with AD risk had been published in previous single gene studies [3] . Against this background, we investigated further genes from the same functional context for association with the risk for AD in a targeted screen of cholesterol-related genes. Full genome scans have identified chromosomal regions with high logarithm of the odds (LOD) scores for AD which supposedly harbor AD susceptibility genes [4, 5] . Because positional candidate gene selection might reduce the prior probability of false positive associations, we confined our screen to AD-linked chromosomal regions [6] .
In this paper, we report that of 28 investigated genes, HMGCS2, FDPS, RAFTLIN, ACAD8, NPC2, and ABCG1 were associated with the risk for sporadic AD in a small screening sample. However, none of the observed associations could be consistently replicated.
Materials and methods

Patients and control subjects
Case control samples for sporadic AD from six independent clinical centers in Switzerland, Germany, Poland, Belgium, Sweden, and Greece were included in genetic association studies. Clinical diagnosis of probable AD was made according to the NINCDS-ADRDA criteria [7] . Dementia and memory deficits in geographically matched control subjects were excluded by neuropsychological testing, consisting of the "Consortium to Establish a Registry for Alzheimer's Disease" (CERAD) neuropsychological test battery and the "mini mental status examination" (MMSE). Cases and controls from the German series were histopathologically confirmed. The local Ethics Committees approved of the study, and informed consent was obtained before the investigation. Table 1 summarizes the sample characteristics. Screening was done in a random subsample of the Swiss series comprising 115 AD cases and 191 healthy control subjects (HCS).
Chromosomal regions
To define chromosomal regions of interest, we used the high-resolution family-based full genome scans by Myers et al. [4] and Blacker et al. [5] as a basis. To transpose the positional information from the Marshfield linkage map to the NCBI sequence map, we used the mapping information of the 'UniSTS integrating markers and maps' data base (http:// www.ncbi.nlm.nih.gov/). We took the sequence map position of the microsatellite marker with the highest signal for a linkage peak as a reference point for our interval of interest. The interval comprised the Z max-1 support interval of the peak marker, all sections of a peak with LOD scores >1, and at least 5 cm upstream and downstream the peak marker assuming a linear correlation of distance between the linkage and the sequence map. For chromosome 10, we investigated an arbitrary interval comprising additional information from several fine mapping studies [8] [9] [10] [11] . Table 2 summarizes the investigated chromosomal regions.
Gene selection
Relation of a gene to cholesterol metabolism was assumed based on the combined information from keyword-based searches of the following databases: NCBI EntrezGene (http://www.ncbi.nlm.nih.gov/), GeneCards (http://bioinfo. weizmann.ac.il/cards/index.shtml) genmap pathways (http://www.genmapp.org), Gene ontology consortium (http://www2.ebi.ac.uk/), The Kegg website: (http://www. genome.ad.jp/kegg/kegg.html). Genes that had an established or probable role in cholesterol metabolism where checked for localization in the chromosomal regions defined above. Conversely, genes in these chromosomal regions were checked for a role in cholesterol metabolism based on the NCBI EntrezGene gene description. Although thorough, this selection process does not warrant completeness. Forty-five (45) genes fulfilled both the functional and the positional inclusion criteria (Table 2) . Fourteen (14) of these genes had been investigated in previous studies with positive or negative results [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] (including unpublished observations). The remaining 28 genes were included in the present study (Table 3) . Intervals representing peak configurations were searched for genes related to cholesterol metabolism. For chromosome 10, information from various studies (var.) [8] [9] [10] [11] was included. Forty-five cholesterol-related genes were identified in these intervals. Genes in italics were associated with AD risk in the screening sample (P≤0.05 in Pearson's χ 2 tests of individual SNPs or haplotypes). a Genes with preexisting association data were not investigated in the present study. 
SNP selection
Information on single nucleotide polymorphisms (SNPs) was derived from the NCBI dbSNP database. Eighty-four (84) SNPs corresponding to a mean resolution of ∼10 kb, on average, ∼40% of the genetic variation of the investigated loci that would be covered by a set of tagging SNPs with a genotype correlation of <90% and a minor allele frequency of >5%, and on average, three SNPs per gene, were selected by the following criteria.
(1) High validation status: Ideally, SNPs reported by several independent sources were selected. (2) Appropriate position: Ideally, the SNPs selected for a gene covered the locus from upstream the 5′ end to downstream the 3′ end (the average position of the most 5′ marker was 2,663 bp upstream of the start codon, and the average position of the most 3′ marker was 230 bp downstream of the stop codon). (3) Informative allele frequencies: Ideally, SNPs with a reported minor allele frequency of >10% were selected. Information on linkage disequilibrium obtained from the Celera data base (SNPbrowser Version 2.0, Applera) was taken into consideration in the decision on SNP number and position. SNPs for which no reliable assay could be established, SNPs that did not show informative allelic distribution in our screening sample, and SNPs with strong distortion of Hardy-Weinberg equilibrium (P<0.01) in the control group of the screening sample were discarded and replaced by new markers. Further markers were also introduced where the most 5′ or 3′ SNPs yielded positive signals to facilitate delimitation from neighboring loci. Table 3 compiles the SNPs investigated as markers for the respective genes (more detailed information on the selected SNPs is provided in "electronic supplementary material" Table 5 ).
Genotyping
Genomic DNA was isolated from ethylenediaminetetraacetic acid blood using QIAamp DNA blood kits (Qiagen). Genotyping was done using the KASPar method (KBiosciences, http://www.kbioscience.co.uk). In the Belgian series, genotyping was done using 2 SEQUENOM mass array spectrometry multiplex assays, except for rs3827225 and rs692382 (direct sequencing) and rs651347 and rs1441008 (Pyrosequencing). On request, we will provide details on the individual assays including primers.
Statistics
To calculate Hardy-Weinberg equilibrium, to analyze linkage, and to reconstruct haplotypes based on pair-wise linkage disequilibrium (LD) between contributing SNPs, we used PowerMarker Version 3.22 (http://www.powermarker.net). We considered only those haplotypes for which the gametic phase could be predicted with a probability of ≥95% in every individual without missing data on contributing SNPs. To assess association with AD, frequencies of genetic markers were compared between AD and HCS groups in Pearson's χ 2 tests (SPSS 12.0 for Windows). Statistical (Table 3 ; on request, genotype details of all markers tested in the screening sample will be provided). Five of six genes showed P values of ≥0.01 (HMGCS2, FDPS, RAFTLIN, ACAD8, NPC2). The only gene significant at a higher level was ABCG1 (rs692383, P=0.0007, allelic association).
To validate these observations, we investigated variants within HMGCS2, FDPS, RAFTLIN, ACAD8, NPC2, and ABCG1 in an enlarged Swiss sample and in five independent replication samples of European origin. We genotyped 19 SNPs that either alone or as haplotypes were associated with AD risk in the screening sample.
Sample enlargement removed the initial significance of HMGCS2, RAFTLIN, and NPC2 in the Swiss series. Association of HMGCS2, FDPS, NPC2, and ABCG1 variants with AD was observed in at least one of the five replication samples on a gene basis at a significance level of P≤0.05. However, effects were contributed by different markers of the same gene (e.g., FDPS: H A-G-A in Switzerland; H A-T-A in Sweden) or had inverse directionality (e.g., ABCG1 H C-G : OR 1.65, 95% CI 1.06-2.59 in Switzerland; OR=0.67, 95% CI=0.46-0.98 in Poland) in different samples (Table 4 , "electronic supplementary material" Tables 1 and 2 ). Exclusion of individuals <65 years of age did not significantly change the results (data not shown).
Previous to sample pooling for combined analyses, we compared sex distribution, age, and APOE ɛ4 prevalence between the control groups of the six samples. Sex distribution and age showed strong center dependence (P<0.000001). Notably, allelic or genotypic frequencies of some investigated SNPs (HMGCS2: rs651347, rs668156; ACAD8: rs570113, rs561945, rs514417; ABCG1: rs1378577) were also distributed differentially across control groups at significance levels of P=0.05 to P= 0.002. This indicated that the comparability of the investigated samples may be limited and that sample admixture may produce false positive or false negative findings in combined analyses. Therefore, we excluded center-dependent genetic markers and haplotypes containing these markers from analyses in the pooled sample (n= 2864). The analysis of all remaining SNPs and haplotypes did not produce consistent association of a locus with AD. Only markers for NPC2 (rs1860108, rs1029699, H G-C-C-C ) were positive at a low significance level (P > 0.01). However, this effect was completely dependent on the observed association of these markers with AD in the small German sample, and logistic regression adjusting for age, sex, center, and APOE removed its significance. Exclusion of the younger participants (<65 years of age) and stratification for sex did not affect the result of the combined analysis. However, stratification for the presence or absence of at least one APOE ɛ4 allele produced an effect of HMGCS2, as rs532208 was associated with AD in the APOE-ɛ4-positive stratum with the G allele as a risk factor and the C allele being protective (n=1182, OR=1.28, 95% CI 1.07-1.53, χ 2 =7.03, P=0.008, P=0.004 after correction for age, sex, center, and all other HMGCS2 markers tested in the combined sample, Tables 5 and 6 ). Rs1441008 was also associated with AD in an APOEdependent manner (Tables 5 and 6 ). Reassessment of the six individual samples revealed association of at least one HMGCS2 marker with AD in the APOE-ɛ4-positive or the APOE-ɛ4-negative stratum for every sample at significance levels of P=0.03-0.002 (Table 7) .
Discussion
In the present study, we have conducted a case control association study with those genes that are functionally related to cholesterol metabolism and are localized in chromosomal regions with high LOD scores for AD and are, therefore, both functional and positional candidate susceptibility genes for AD. During screening in a limited cohort of AD patients and healthy control subjects, most of the genes investigated with, on average, three SNPs were negative and were excluded from further analyses. This does not definitely exclude that these genes may be associated with AD because the statistical power of the screening process was low (the relative risk detectable with 80% power at a significance level of P=0.05 was 0.224 or 2.525 for a marker with a minor allele frequency of 0.1), and the markers used for the investigated genes did not capture the whole genetic variability of the respective loci in terms of linkage and allele frequencies. Notably, recent studies have shown that even a dense set of tagging SNPs may be insufficient to definitely exclude association [26, 27] . Six genes, HMGCS2, FDPS, RAFTLIN, ACAD8, NPC2, and Statistics refer to the comparison of the numbers of G vs T alleles (rs532208) between the HCS and AD group. The italicized P value refers to the unadjusted Pearson's χ 2 test. The P value in parentheses was obtained by logistic regression adjusting for sex, age, center, and all HMGCS2 markers tested in the pooled sample. P values in italics refer to unadjusted Pearson's χ 2 tests. P values in parentheses were obtained by logistic regressions adjusting for sex, age, APOE, and all markers of the respective gene. Odds ratios (OR) and corresponding confidence intervals (CI) refer to presence of the indicated allele or genotype of the respective SNP and to presence of the haplotype (H). Haplotype-defining alleles of the contributing SNPs are indicated from 5′ to 3′ according to Table 3 . a Haplotypes of ABCG1 comprise only rs1378577 and rs692383. Statistical details are given for the strongest effect. The other listed markers were positive on a lower significance level. Genotypic and haplotypic distributions are provided as "electronic supplementary material" (Tables 1 and 2) ABCG1, were positive, assuming statistical significance at nominal P values of ≤0.05. Only ABCG1 was associated with AD at a substantially higher significance level.
To test if these observations were of any relevance beyond the investigated screening sample, we genotyped positive markers in an enlarged sample and in five independent Caucasian samples from different European countries. None of the markers showed a consistent effect across the investigated samples. Only stratification for the presence or absence of at least one APOE ɛ4 allele revealed a weak effect of HMGCS2. These findings argue against major effects of the investigated genetic variants on AD risk.
Significant differences between the control groups of the individual samples in age, sex distribution, and, notably, allelic and genotypic frequencies of some of the SNPs investigated in the present study limited the significance of a pooled analysis. Separate analyses of the samples confirmed association of HMGCS2, FDPS, NPC2, and ABCG1 with AD in at least one sample. However, across the samples, effects were carried by different SNPs or haplotypes, or the same markers showed inverse odds ratios. Our findings reflect the common problem of replication failure and inconsistency in case control association studies. It may be explained by false positivity of the original observation, i.e., type I errors. Populationspecific effects of the investigated genes, owing to genetic background and environmental factors, may also explain inconsistencies between trials in independent samples. Differences in linkage and allele frequencies between different samples may lead to population-specific validity of genetic markers, which can explain inconsistency and inverse directionality of associations when the investigated genetic markers are not the functional variables underlying the observed effects. Moreover, differences in the distribu- Table 7 All HMGCS2 markers that showed APOE-dependent associated with AD in the individual samples Italicized P values refer to unadjusted Pearson's χ 2 tests. P values in parentheses were obtained by logistic regressions adjusting for sex, age, and all HMGCS2 markers. Odds ratios (OR) and corresponding confidence intervals (CI) refer to presence of the indicated allele or genotype of the respective SNP and to presence of the haplotype (H). Haplotype-defining alleles of the contributing SNPs are indicated from 5′ to 3′ according to Table 3 . Genotypic and haplotypic distributions are provided as "electronic supplementary material" (Tables 3 and 4) Statistics refer to the comparison of the numbers of C vs T alleles (rs1441008) between the HCS and AD group. The italicized P value refers to the unadjusted Pearson's χ 2 test. The P value in parentheses was obtained by logistic regression adjusting for sex, age, center, and all HMGCS2 markers tested in the pooled sample.
tion of factors like sex and age may affect the result of replication trials even if the investigated populations are genetically similar and share a similar environment. These explanations may also apply for the present study.
Although only at low significance levels, we found limited confirming evidence for association of HMGCS2, FDPS, NPC2, and ABCG1 with AD. Therefore, these genes may be discussed separately:
HMGCS2 (GeneID: 3158, NCBI Entrez Gene database, http://www.ncbi.nlm.nih.gov/) encodes 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2. HMGCS2 is a homologue of HMGCS1, a key enzyme in sterol biosynthesis and is localized in the mitochondrion. It is the first and regulating enzyme of the ketogenic pathway. Association of this gene with AD in APOE ɛ4 allele carriers from the pooled sample is in line with the APOE dependence of the linkage peak on chromosome 1 in the full genome scan by Myers et al. [4] . Separate analyses of the six samples consistently showed APOE-dependent association of HMGCS2 markers with AD. However, across samples, these associations were observed for different markers, showed different strength and directionality, and occurred both in APOE-ɛ4-positive and in APOE-ɛ4-negative strata. The interpretability of these observations is limited by the small number of individuals in most of the sample strata. Pure stratification artifacts seem unlikely because APOEdependent association of at least one HMGCS2 marker with AD was observed in every sample. We assume that there may be complex epistatic interactions between APOE and genetic variables in LD with the investigated HMGCS2 markers that may directly or indirectly lead to the observed effects. Other loci (PHGDH, REG4) are mapped in close vicinity to HMGCS2. Therefore, definite attribution of the signal to HMGCS2 would require fine mapping of the region and possibly functional data in support of a role of HMGCS2 in AD.
FDPS (GeneID: 2224, NCBI Entrez Gene database, http://www.ncbi.nlm.nih.gov/) encodes farnesyl diphosphate synthase. FDPS is a key enzyme in the isoprene biosynthetic pathway, which provides the cell with cholesterol. Like for HMGCS2, definite attribution of the signal to the gene is not possible with the present set of markers (neighboring loci: PKLR, RUSC1). NPC2 (GeneID: 10577, NCBI Entrez Gene database, http://www.ncbi.nlm.nih.gov/) encodes Niemann-Pick disease type C2. NPC2 may be involved in regulating the transport of cholesterol through the late endosomal/lysosomal system. Mutations in this gene have been associated with Niemann-Pick disease type C2 and frontal lobe atrophy. Also, here, delimitation of the signal from neighboring loci (HBLD1, LTBP2) would require further analyses.
ABCG1 (GeneID: 9619, NCBI Entrez Gene database, http://www.ncbi.nlm.nih.gov/) encodes ATP-binding cassette transporter G1. ABCG1 is a half-size transporter that, as a dimer, mediates cholesterol efflux via HDL particles. Association of the related genes ABCA1 [16, 28, 29] and ABCA2 [26, 30] with AD may be indirect support for a similar effect of ABCG1. Association of paralogous genes with AD has also been described for members of the GAPD gene family [31] . The gene encoding the ABCG1 dimerization partner ABCG4 was also investigated in the present study, but was not associated with AD. We were able to delineate the ABCG1 signal in the 5′ region of the gene. Therefore, it seems unlikely that it stems from LD with a different locus.
In previous studies, we and others have investigated several genes related to the metabolism of cholesterol for association with AD. Most of these studies were done with very few markers of the respective genes, and independent replication studies produced inconsistent results (The AlzGene Database, http://www.alzgene.org). In a more systematic approach, we have now investigated variants of hitherto uninvestigated cholesterol-related genes that are located in AD-linked chromosomal regions. The results of this study reflect the outcome of previous association studies that replication trials in independent populations yield only inconsistent confirmative evidence for initially observed associations. Of the cholesterol-related genes for which we have described, association with AD CYP46A [32] and ABCA1 [16] may be quoted as examples of loci with several positive replication studies that are negative in meta-analyses because of reciprocal effects between individual populations (The AlzGene Database, http://www. alzgene.org). On the other hand, individual replication studies on an association of SOAT1 [12] with AD were negative, but meta-analyses support a role of this gene in AD (The AlzGene Database, http://www.alzgene.org).
The genetic variants investigated in the present study are not associated with a strong and general modification of the risk for AD. However, inconsistent findings for HMGCS2, FDPS, NPC2, and ABCG1 may provide some support for a role of further cholesterol-related genes in AD and may warrant fine mapping studies of these loci. We assume that identification of the functional variants that underlie associations observed for the genetic markers investigated in the present and in previous studies may help to overcome the prevalent problem of inconsistent replications. Once identified, these variants may form a cluster that, together with the APOE ɛ2/3/4 haplotype, may genetically link cholesterol metabolism and AD. Thus, the present study may contribute to the uncovering of the complex genetic underpinnings of this disease. 
